Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20733294 | 0.81 | RPS6KA3 (0.35) | GSK3BDYRK1ARPS6KA3JAK2AXL | |
| SCHEMBL20733256 | 0.74 | FGFR4 (0.41) | — | |
| SCHEMBL20720993 | 0.72 | JAK2 (0.35) | GSK3BDYRK1AMAPK1RORCPTGES | |
| SCHEMBL17778615 | 0.72 | JAK2 (0.35) | GSK3BDYRK1AMAPK1RORCPTGES | |
| SCHEMBL16775802 | 0.64 | SMN1; SMN2 (0.36) | RPS6KA3RPS6KA2 | |
| SCHEMBL20733111 | 0.63 | MAPK14 (0.36) | MAPK1 | |
| SCHEMBL19736443 | 0.63 | GSK3B (0.39) | GSK3BDYRK1ARPS6KA3 | |
| SCHEMBL20733150 | 0.63 | PTGER4 (0.39) | RPS6KA3RPS6KA2 | |
| SCHEMBL31274588 | 0.62 | HDAC4 (0.41) | GSK3BDYRK1AMAPK1 | |
| SCHEMBL31275597 | 0.62 | HDAC4 (0.41) | GSK3BDYRK1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2340/4885DYRK1A 2959/4885DHODH 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.